XML 71 R54.htm IDEA: XBRL DOCUMENT v3.25.0.1
Investments in Non-Marketable Securities - Narrative (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Mar. 31, 2023
Jul. 31, 2022
Dec. 31, 2021
Dec. 31, 2024
Sep. 30, 2024
Dec. 31, 2023
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Nov. 30, 2023
Mar. 31, 2022
Equity Securities without Readily Determinable Fair Value [Line Items]                          
Investments in non-marketable securities                 $ 0 $ 1,191 $ 5,300    
Investment in non-marketable equity securities       $ 2,798   $ 9,700     2,798 9,700      
Revenues                 59,345 70,143 138,590    
Impairment of investment in non-marketable securities                 6,902 12,215 0    
Equity securities without readily determinable fair value, upward price adjustment, annual amount                     200    
Equity securities without readily determinable fair value, upward (downward) price adjustment, annual amount                 0 0      
Research and development revenue                          
Equity Securities without Readily Determinable Fair Value [Line Items]                          
Revenues                 22,559 27,237 21,914    
seqWell | Research and development revenue                          
Equity Securities without Readily Determinable Fair Value [Line Items]                          
Revenues                 $ 200        
Common Stock | seqWell                          
Equity Securities without Readily Determinable Fair Value [Line Items]                          
Stock issued during period, shares, issued for services (in shares)                 205,279        
seqWell                          
Equity Securities without Readily Determinable Fair Value [Line Items]                          
Equity securities without readily determinable fair value (in shares)                         1,000,000
Investment in non-marketable equity securities       2,416   2,625     $ 2,416 2,625     $ 5,000
Impairment of investment in non-marketable securities       $ (2,800)     $ 3,000   200        
Arzeda                          
Equity Securities without Readily Determinable Fair Value [Line Items]                          
Impairment of investment in non-marketable securities           $ 1,200              
Related Party | Research and development revenue                          
Equity Securities without Readily Determinable Fair Value [Line Items]                          
Revenues                 $ 0 0 $ 1,245    
MAI                          
Equity Securities without Readily Determinable Fair Value [Line Items]                          
Impairment of investment in non-marketable securities         $ (3,900)                
MAI                          
Equity Securities without Readily Determinable Fair Value [Line Items]                          
Impairment of investment in non-marketable securities                   $ 8,000      
Series B Preferred Stock | MAI | Related Party                          
Equity Securities without Readily Determinable Fair Value [Line Items]                          
Milestone payments received (in shares)   1,587,049 1,587,049         1,587,049          
Series B Preferred Stock | Arzeda                          
Equity Securities without Readily Determinable Fair Value [Line Items]                          
Equity securities without readily determinable fair value (in shares)                       207,070  
Series B Preferred Stock | MAI                          
Equity Securities without Readily Determinable Fair Value [Line Items]                          
Investment owned, balance (in shares) 985,545                        
Investments in non-marketable securities $ 800                        
Common Stock | seqWell                          
Equity Securities without Readily Determinable Fair Value [Line Items]                          
Equity securities without readily determinable fair value (in shares)       205,279         205,279        
Common Stock | Arzeda                          
Equity Securities without Readily Determinable Fair Value [Line Items]                          
Convertible preferred stock, shares issued upon conversion (in shares)                       41,414  
Series A and B Preferred Stock | MAI | Related Party                          
Equity Securities without Readily Determinable Fair Value [Line Items]                          
Noncash or part noncash acquisition, noncash financial or equity instrument consideration, shares issued (in shares)                 19,277,914        
Series C-1 Preferred Stock | seqWell                          
Equity Securities without Readily Determinable Fair Value [Line Items]                          
Equity securities without readily determinable fair value (in shares)             88,256            
Common Stock Warrants | seqWell                          
Equity Securities without Readily Determinable Fair Value [Line Items]                          
Equity securities without readily determinable fair value (in shares)       44,128     44,128   44,128        
Investment in non-marketable equity securities             $ 400            
Series C And C-1 Preferred Stock | seqWell                          
Equity Securities without Readily Determinable Fair Value [Line Items]                          
Equity securities without readily determinable fair value (in shares)       1,088,256         1,088,256